179. Williams syndrome Clinical trials / Disease details
Clinical trials : 5 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04095585 (ClinicalTrials.gov) | September 2014 | 16/9/2019 | Molecular Characterization of Patients Affected by Williams Syndrome and Autism. | Molecular Investigation, Using Chromosomal Microarray and Whole Exome Sequencing, of Patients Affected by Williams Beuren Syndrome and Autism Spectrum Disorder | Williams Beuren Syndrome;Autism Spectrum Disorder | Genetic: chromosomal microarray analysis (CMA) and whole exome sequencing (WES) | Hospices Civils de Lyon | NULL | Completed | N/A | N/A | All | 6 | NULL | |
| 2 | EUCTR2007-006059-37-ES (EUCTR) | 27/05/2009 | 19/08/2008 | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS | Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1. MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome | Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula INN or Proposed INN: LOSARTAN POTASICO Other descriptive name: LOSARTAN POTASSIUM | Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Spain | |||
| 3 | EUCTR2006-005745-11-FR (EUCTR) | 03/04/2008 | 06/02/2008 | Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé | Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé | Williams syndrome MedDRA version: 9.1;Level: LLT;Classification code 10049644;Term: Williams syndrome | Trade Name: LONOTEN INN or Proposed INN: MINOXIDIL | Hospices Civils de Lyon | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| 4 | NCT00768820 (ClinicalTrials.gov) | May 2001 | 7/10/2008 | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome | The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors | Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome | Drug: methylphenidate, fluoxetin, risperidone | The Chaim Sheba Medical Center | NULL | Recruiting | N/A | N/A | All | 400 | Phase 4 | Israel |
| 5 | NCT00013962 (ClinicalTrials.gov) | September 1998 | 3/4/2001 | Vitamin D Metabolism and the Williams Syndrome | Vitamin D Metabolism and the Williams Syndrome | Williams Syndrome | Drug: Vitamin D | National Center for Research Resources (NCRR) | NULL | Completed | 18 Years | 50 Years | Both | N/A | United States |